"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Descriptor ID |
D011087
|
| MeSH Number(s) |
C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
|
| Concept/Terms |
Polycythemia Vera- Polycythemia Vera
- Primary Polycythemia
- Polycythemia, Primary
- Polycythemias, Primary
- Primary Polycythemias
- Polycythemia Rubra Vera
- Polycythemia Rubra Veras
- Vera, Polycythemia Rubra
- Veras, Polycythemia Rubra
- Polycythemia Ruba Vera
- Polycythemia Ruba Veras
- Ruba Vera, Polycythemia
- Ruba Veras, Polycythemia
- Vera, Polycythemia Ruba
- Veras, Polycythemia Ruba
- Osler-Vaquez Disease
- Disease, Osler-Vaquez
- Osler Vaquez Disease
- Erythremia
- Erythremias
|
Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".
Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".
This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 13 | 3 | 16 |
| 2018 | 13 | 1 | 14 |
| 2019 | 4 | 0 | 4 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.
-
Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021 12 01; 96(12):1580-1586.
-
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021 07 29; 14(1):119.
-
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response. Ann Rheum Dis. 2021 10; 80(10):1361-1362.
-
Hydroxyurea-induced genital ulcers and erosions: Two case reports. J Tissue Viability. 2021 Aug; 30(3):462-464.
-
Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. Am J Hematol. 2021 06 01; 96(6):E200-E203.
-
Case of COVID-19 infection and polycythaemia presenting with massive acute pulmonary embolism. BMJ Case Rep. 2020 Sep 18; 13(9).
-
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. Am J Hematol. 2020 01; 95(1):E1-E3.
-
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019 08; 8(9):4089-4092.
-
Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):e204-e208.
-
Comments on pre-fibrotic myelofibrosis and how should it be managed. Br J Haematol. 2019 07; 186(2):358-360.